155 related articles for article (PubMed ID: 38745123)
1. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).
Quintanilha JCF; Sibley AB; Liu Y; Niedzwiecki D; Halabi S; Rogers L; O'Neil B; Kindler H; Kelly W; Venook A; McLeod HL; Ratain MJ; Nixon AB; Innocenti F; Owzar K
BMC Genomics; 2024 May; 25(1):473. PubMed ID: 38745123
[TBL] [Abstract][Full Text] [Related]
2. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-
Quintanilha JCF; Sibley AB; Liu Y; Niedzwiecki D; Halabi S; Rogers L; O'Neil B; Kindler H; Kelly W; Venook A; McLeod HL; Ratain MJ; Nixon AB; Innocenti F; Owzar K
medRxiv; 2023 Dec; ():. PubMed ID: 38106038
[TBL] [Abstract][Full Text] [Related]
3. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
Innocenti F; Sibley AB; Patil SA; Etheridge AS; Jiang C; Ou FS; Howell SD; Plummer SJ; Casey G; Bertagnolli MM; McLeod HL; Auman JT; Blanke CD; Furukawa Y; Venook AP; Kubo M; Lenz HJ; Parker JS; Ratain MJ; Owzar K
Clin Cancer Res; 2021 Jan; 27(1):267-275. PubMed ID: 32958699
[TBL] [Abstract][Full Text] [Related]
4. Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD.
Sun W; Kechris K; Jacobson S; Drummond MB; Hawkins GA; Yang J; Chen TH; Quibrera PM; Anderson W; Barr RG; Basta PV; Bleecker ER; Beaty T; Casaburi R; Castaldi P; Cho MH; Comellas A; Crapo JD; Criner G; Demeo D; Christenson SA; Couper DJ; Curtis JL; Doerschuk CM; Freeman CM; Gouskova NA; Han MK; Hanania NA; Hansel NN; Hersh CP; Hoffman EA; Kaner RJ; Kanner RE; Kleerup EC; Lutz S; Martinez FJ; Meyers DA; Peters SP; Regan EA; Rennard SI; Scholand MB; Silverman EK; Woodruff PG; O'Neal WK; Bowler RP; ;
PLoS Genet; 2016 Aug; 12(8):e1006011. PubMed ID: 27532455
[TBL] [Abstract][Full Text] [Related]
5. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
Lambrechts D; Thienpont B; Thuillier V; Sagaert X; Moisse M; Peuteman G; Pericay C; Folprecht G; Zalcberg J; Zilocchi C; Margherini E; Chiron M; Van Cutsem E
Br J Cancer; 2015 Sep; 113(7):1027-34. PubMed ID: 26355232
[TBL] [Abstract][Full Text] [Related]
7. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Hatch AJ; Sibley AB; Starr MD; Brady JC; Jiang C; Jia J; Bowers DL; Pang H; Owzar K; Niedzwiecki D; Innocenti F; Venook AP; Hurwitz HI; Nixon AB;
Cancer Med; 2016 Sep; 5(9):2249-60. PubMed ID: 27465221
[TBL] [Abstract][Full Text] [Related]
8. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.
Bencsikova B; Budinska E; Selingerova I; Pilatova K; Fedorova L; Greplova K; Nenutil R; Valik D; Obermannova R; Sheard MA; Zdrazilova-Dubska L
BMC Cancer; 2019 Jul; 19(1):687. PubMed ID: 31307428
[TBL] [Abstract][Full Text] [Related]
9. LncRNA MIR503HG is downregulated in Han Chinese with colorectal cancer and inhibits cell migration and invasion mediated by TGF-β2.
Chuo D; Liu F; Chen Y; Yin M
Gene; 2019 Sep; 713():143960. PubMed ID: 31278965
[TBL] [Abstract][Full Text] [Related]
10. An optimal variant to gene distance window derived from an empirical definition of cis and trans protein QTLs.
Fauman EB; Hyde C
BMC Bioinformatics; 2022 May; 23(1):169. PubMed ID: 35527238
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.
Suenaga M; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Yamaguchi T; Lenz HJ
Int J Cancer; 2019 May; 144(10):2567-2577. PubMed ID: 30411783
[TBL] [Abstract][Full Text] [Related]
12. A genome-wide association study identifies protein quantitative trait loci (pQTLs).
Melzer D; Perry JR; Hernandez D; Corsi AM; Stevens K; Rafferty I; Lauretani F; Murray A; Gibbs JR; Paolisso G; Rafiq S; Simon-Sanchez J; Lango H; Scholz S; Weedon MN; Arepalli S; Rice N; Washecka N; Hurst A; Britton A; Henley W; van de Leemput J; Li R; Newman AB; Tranah G; Harris T; Panicker V; Dayan C; Bennett A; McCarthy MI; Ruokonen A; Jarvelin MR; Guralnik J; Bandinelli S; Frayling TM; Singleton A; Ferrucci L
PLoS Genet; 2008 May; 4(5):e1000072. PubMed ID: 18464913
[TBL] [Abstract][Full Text] [Related]
13. Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).
Raghav K; Ou FS; Venook AP; Innocenti F; Sun R; Lenz HJ; Kopetz S
J Clin Oncol; 2023 Jan; 41(3):472-478. PubMed ID: 36067452
[No Abstract] [Full Text] [Related]
14. Identification of cis-regulatory variation influencing protein abundance levels in human plasma.
Lourdusamy A; Newhouse S; Lunnon K; Proitsi P; Powell J; Hodges A; Nelson SK; Stewart A; Williams S; Kloszewska I; Mecocci P; Soininen H; Tsolaki M; Vellas B; Lovestone S; ; Dobson R;
Hum Mol Genet; 2012 Aug; 21(16):3719-26. PubMed ID: 22595970
[TBL] [Abstract][Full Text] [Related]
15. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M
Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.
Jia J; Howard L; Liu Y; Starr MD; Brady JC; Niedzwiecki D; Strickler JH; Nixon AB
Cancer Chemother Pharmacol; 2022 Mar; 89(3):413-422. PubMed ID: 35171350
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
Pohl A; El-Khoueiry A; Yang D; Zhang W; Lurje G; Ning Y; Winder T; Hu-Lieskoven S; Iqbal S; Danenberg KD; Kahn M; Teo JL; Shriki J; Stebbing J; Lenz HJ
Pharmacogenomics J; 2013 Apr; 13(2):173-80. PubMed ID: 22231565
[TBL] [Abstract][Full Text] [Related]
19. Identification of cis- and trans-acting genetic variants explaining up to half the variation in circulating vascular endothelial growth factor levels.
Debette S; Visvikis-Siest S; Chen MH; Ndiaye NC; Song C; Destefano A; Safa R; Azimi Nezhad M; Sawyer D; Marteau JB; Xanthakis V; Siest G; Sullivan L; Pfister M; Smith H; Choi SH; Lamont J; Lind L; Yang Q; Fitzgerald P; Ingelsson E; Vasan RS; Seshadri S
Circ Res; 2011 Aug; 109(5):554-63. PubMed ID: 21757650
[TBL] [Abstract][Full Text] [Related]
20. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
